
    
      Subjects will receive one of two treatment regimens:

      Group A: intravenous infusion of pegylated liposomal doxorubicin（PLD） 35 mg/m2, d1;
      cyclophosphamide 600 mg/m2, intravenous infusion, d1; once every 21days, for 4 cycles.
      Sequential docetaxel 100 mg/m2, intravenous infusion, d1, or paclitaxel 80mg/m2,intravenous
      infusion, d1,8,15, once every 21 days, for 4 cycles.

      Group B: intravenous infusion of doxorubicin 60 mg/m2, d1; cyclophosphamide 600 mg/m2,
      intravenous infusion, d1; sequential docetaxel 100 mg/m2, intravenous infusion, d1, or
      paclitaxel 80mg/m2,intravenous infusion, d1,8,15, once every 21days, for 4 cycles. The
      primary endpoint is cardiotoxity,the secondary endpoint is 5-year disease-free survival
      (DFS), 5-year overall survival (OS), and safety: hematology and non hematological toxicity.
    
  